Al in Pathology Market by Neural Network(GAN, CNN, RNN),Function(Diagnostic, Image Analysis, CDSS, Data Management, Analytics),Use Case(Drug Discovery, Clinical Workflow),End User(Hospitals, Labs, Pharma/Biotech), & Region-Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 KEY STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Revenue share analysis illustration
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 KEY OPPORTUNITIES FOR PLAYERS IN AI IN PATHOLOGY MARKET
• 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER AND KEY COUNTRY/REGION
• 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Development of CNNs and advanced AI models
    • 5.2.1.2 Integration of AI into multiplex imaging
    • 5.2.1.3 Increasing cases of misdiagnoses in patients
    • 5.2.1.4 Benefits of AI-augmented telepathology
    • 5.2.1.5 Advancements in deep learning & image processing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of digital pathology systems
    • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
    • 5.2.2.3 Inadequate interoperability issues with legacy systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing demand for personalized medicines
    • 5.2.3.2 Integration of multi-omics data
    • 5.2.3.3 Predictive analytics for disease progression
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Insufficient data for AI algorithms
    • 5.2.4.2 Data privacy and ethical concerns
    • 5.2.4.3 Challenges associated with interpretability of AI models
• 5.3 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 INDUSTRY TRENDS
  • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Machine learning (ML) and artificial intelligence (AI)
    • 5.7.1.2 Computer vision
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Cloud computing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Telepathology
• 5.8 REGULATORY LANDSCAPE
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATIONS, BY REGION
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.9.2 INDICATIVE PRICING ANALYSIS, BY OFFERING
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT FROM NEW ENTRANTS
  • 5.10.2 THREAT FROM SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
  • 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 END USER ANALYSIS
  • 5.13.1 UNMET NEEDS OF END USERS
  • 5.13.2 END USER EXPECTATIONS
• 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES
  • 5.15.2 CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS
  • 5.15.3 CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 BUSINESS MODELS
• 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY
    • 5.18.2.1 Accelerated biomarker discovery and clinical trial optimization
  • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.3.1 Drug discovery & development market
    • 5.18.3.2 Medical imaging & diagnostics market
  • 5.18.4 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.4.1 User readiness
      • 5.18.4.1.1 Pharmaceutical companies
      • 5.18.4.1.2 Biopharmaceutical companies
    • 5.18.4.2 Impact assessment
      • 5.18.4.2.1 User A: Pharmaceutical companies
        • 5.18.4.2.1.1 Implementation
        • 5.18.4.2.1.2 Impact
      • 5.18.4.2.2 User B: Biopharmaceutical companies
        • 5.18.4.2.2.1 Implementation
        • 5.18.4.2.2.2 Impact
• 5.19 TRADE ANALYSIS
  • 5.19.1 IMPORT SCENARIO
  • 5.19.2 EXPORT SCENARIO
• 5.20 US 2025 TARIFF
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON COUNTRY/REGION
    • 5.20.4.1 US
    • 5.20.4.2 Europe
    • 5.20.4.3 Asia Pacific
  • 5.20.5 IMPACT ON END USE INDUSTRIES

6 AI IN PATHOLOGY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
• 6.3 NICHE POINT SOLUTIONS
  • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
• 6.4 TECHNOLOGY
  • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET
• 6.5 HARDWARE
  • 6.5.1 HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET
• 6.6 MICROSCOPES
  • 6.6.1 NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH
• 6.7 SCANNERS
  • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
• 6.8 STORAGE SYSTEMS
  • 6.8.1 NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

• 7.1 INTRODUCTION
• 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
  • 7.2.1 FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
• 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
  • 7.3.1 NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
• 7.4 RECURRENT NEURAL NETWORKS (RNNS)
  • 7.4.1 NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET
• 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

• 8.1 INTRODUCTION
• 8.2 IMAGE ANALYSIS
  • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
• 8.3 DIAGNOSTICS
  • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
• 8.4 WORKFLOW MANAGEMENT
  • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
• 8.5 DATA MANAGEMENT
  • 8.5.1 EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND
• 8.6 PREDICTIVE ANALYTICS
  • 8.6.1 GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET
• 8.7 CDSS
  • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
• 8.8 AUTOMATED REPORT GENERATION
  • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
• 8.9 QUALITY ASSURANCE TOOLS
  • 8.9.1 RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH

9 AI IN PATHOLOGY MARKET, BY USE CASE

• 9.1 INTRODUCTION
• 9.2 DRUG DISCOVERY
  • 9.2.1 TARGET IDENTIFICATION & SELECTION
    • 9.2.1.1 Analysis of molecular and histological data for biomarker discovery to fuel market
  • 9.2.2 TARGET VALIDATION
    • 9.2.2.1 Increasing demand for precision medicines to drive market
  • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
    • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
  • 9.2.4 HIT-TO-LEAD IDENTIFICATION
    • 9.2.4.1 Advancements in ML to support market growth
  • 9.2.5 LEAD OPTIMIZATION
    • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
  • 9.2.6 CANDIDATE SELECTION & VALIDATION
    • 9.2.6.1 Critical requirement for regulatory approvals to drive market
• 9.3 DISEASE DIAGNOSIS & PROGNOSIS
  • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
• 9.4 CLINICAL WORKFLOW
  • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
• 9.5 TRAINING & EDUCATION
  • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
• 10.3 HOSPITALS & REFERENCE LABORATORIES
  • 10.3.1 INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND

11 AI IN PATHOLOGY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK
  • 11.3.2 UK
    • 11.3.2.1 Increased focus on drug discovery and development to boost demand
  • 11.3.3 GERMANY
    • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
  • 11.3.4 FRANCE
    • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
  • 11.3.5 ITALY
    • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Increased workforce shortage to fuel market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Rising cases of infectious and chronic diseases to fuel demand
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to propel market
  • 11.4.4 INDIA
    • 11.4.4.1 Growing focus on healthcare digitization to boost demand
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Strategic investments for AI adoption to support market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growth in pharmaceutical R&D to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Increasing investments for expansion of technological expertise to support growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Offering footprint
    • 12.5.5.3 Use case footprint
    • 12.5.5.4 End user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches & approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 HOLOGIC, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product/Service launches & approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 AKOYA BIOSCIENCES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 AIFORIA TECHNOLOGIES PLC
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 INDICA LABS INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 OPTRASCAN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Other developments
  • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 MINDPEAK GMBH
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service launches & approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 TRIBUN HEALTH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 TECHCYTE, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product/Service launches & approvals
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Other developments
  • 13.1.12 DEEP BIO INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 LUMEA INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 VISIOPHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product/Service launches & approvals
      • 13.1.14.3.2 Expansions
  • 13.1.15 AETHERAI
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 AIOSYN
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products/Services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product/Service launches & approvals
      • 13.1.16.3.2 Deals
      • 13.1.16.3.3 Other developments
  • 13.1.17 PAIGE AI, INC.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products/Services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product/Service launches & approvals
      • 13.1.17.3.2 Deals
      • 13.1.17.3.3 Other developments
  • 13.1.18 PROSCIA, INC.
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products/Services offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product/Service launches & approvals
      • 13.1.18.3.2 Deals
      • 13.1.18.3.3 Other developments
  • 13.1.19 PATHAI, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products/Services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product/Service launches & approvals
      • 13.1.19.3.2 Deals
  • 13.1.20 TEMPUS LABS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products/Services offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Product/Service launches & approvals
• 13.2 OTHER PLAYERS
  • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
  • 13.2.2 DOMORE DIAGNOSTICS AS
  • 13.2.3 QRITIVE
  • 13.2.4 DEEPATHOLOGY LTD
  • 13.2.5 4D PATH INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 EXCHANGE RATES, 2021-2024
• TABLE 2 ROLE OF PLAYERS IN MARKET ECOSYSTEM
• TABLE 3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
• TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 6 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES
• TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
• TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
• TABLE 10 INDICATIVE PRICING ANALYSIS, BY OFFERING
• TABLE 11 IMPACT OF PORTER'S FORCES
• TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET
• TABLE 13 KEY PATENTS IN AI IN PATHOLOGY MARKET
• TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
• TABLE 15 KEY BUYING CRITERIA, BY END USER
• TABLE 16 UNMET NEEDS OF END USERS
• TABLE 17 AI IN PATHOLOGY MARKET: END USER EXPECTATIONS
• TABLE 18 LIST OF CONFERENCES AND EVENTS, 2025-2026
• TABLE 19 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD THOUSAND)
• TABLE 20 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD MILLION)
• TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US
• TABLE 22 TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS
• TABLE 23 EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT
• TABLE 24 AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 25 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 26 AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 27 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 28 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 29 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 30 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 31 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 32 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 33 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 34 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 35 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 36 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 37 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 38 AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 39 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 40 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 41 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 42 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 43 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 44 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 45 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 46 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 47 AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 48 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
• TABLE 49 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 50 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 51 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 52 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 53 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 54 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 55 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 56 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 57 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 58 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 59 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 60 AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 61 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 62 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 63 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 64 AI IN PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 69 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 70 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 71 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 72 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 73 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 74 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 75 US: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 79 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 80 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 85 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 86 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 87 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 88 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 89 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 90 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 91 UK: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 95 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 96 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 100 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 101 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 105 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 106 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 110 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 111 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 115 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 116 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 121 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 122 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 126 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 127 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 128 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 132 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 133 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 137 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 138 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 142 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 143 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 148 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 149 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 153 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 154 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 158 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 159 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 163 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 164 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 169 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 170 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 174 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 175 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
• TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
• TABLE 179 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
• TABLE 180 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 181 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
• TABLE 182 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
• TABLE 183 OFFERING FOOTPRINT
• TABLE 184 USE CASE FOOTPRINT
• TABLE 185 END USER FOOTPRINT
• TABLE 186 REGION FOOTPRINT
• TABLE 187 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 188 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 189 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 190 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021-APRIL 2025
• TABLE 191 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021- APRIL 2025
• TABLE 192 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
• TABLE 193 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
• TABLE 194 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 195 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 196 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 197 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2025
• TABLE 198 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-MARCH 2025
• TABLE 199 HOLOGIC, INC.: COMPANY OVERVIEW
• TABLE 200 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 201 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 202 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 203 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
• TABLE 204 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 205 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
• TABLE 206 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
• TABLE 207 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021-APRIL 2025
• TABLE 208 INDICA LABS INC.: COMPANY OVERVIEW
• TABLE 209 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
• TABLE 210 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 211 INDICA LABS INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 212 INDICA LABS INC.: EXPANSIONS, JANUARY 2021-APRIL 2025
• TABLE 213 OPTRASCAN: COMPANY OVERVIEW
• TABLE 214 OPTRASCAN: PRODUCTS/SERVICES OFFERED
• TABLE 215 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
• TABLE 216 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
• TABLE 217 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 218 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 219 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021-APRIL 2025
• TABLE 220 MINDPEAK GMBH: COMPANY OVERVIEW
• TABLE 221 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
• TABLE 222 MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 223 MINDPEAK GMBH: DEALS, JANUARY 2021-APRIL 2025
• TABLE 224 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
• TABLE 225 TRIBUN HEALTH: COMPANY OVERVIEW
• TABLE 226 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
• TABLE 227 TRIBUN HEALTH: DEALS, JANUARY 2021-APRIL 2025
• TABLE 228 TECHCYTE, INC.: COMPANY OVERVIEW
• TABLE 229 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 230 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 231 TECHCYTE, INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 232 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
• TABLE 233 DEEP BIO INC.: COMPANY OVERVIEW
• TABLE 234 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
• TABLE 235 DEEP BIO INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 236 LUMEA INC.: COMPANY OVERVIEW
• TABLE 237 LUMEA INC.: PRODUCTS/SERVICES OFFERED
• TABLE 238 LUMEA INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 239 VISIOPHARM: COMPANY OVERVIEW
• TABLE 240 VISIOPHARM: PRODUCTS/SERVICES OFFERED
• TABLE 241 VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 242 VISIOPHARM: EXPANSIONS, JANUARY 2021- APRIL 2025
• TABLE 243 AETHERAI: COMPANY OVERVIEW
• TABLE 244 AETHERAI: PRODUCTS/SERVICES OFFERED
• TABLE 245 AETHERAI: DEALS, JANUARY 2021- APRIL 2025
• TABLE 246 AIOSYN: COMPANY OVERVIEW
• TABLE 247 AIOSYN: PRODUCTS/SERVICES OFFERED
• TABLE 248 AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 249 AIOSYN: DEALS, JANUARY 2021-APRIL 2025
• TABLE 250 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
• TABLE 251 PAIGE AI, INC.: COMPANY OVERVIEW
• TABLE 252 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 253 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021- APRIL 2025
• TABLE 254 PAIGE AI, INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 255 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
• TABLE 256 PROSCIA, INC.: COMPANY OVERVIEW
• TABLE 257 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 258 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 259 PROSCIA, INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 260 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
• TABLE 261 PATHAI, INC.: COMPANY OVERVIEW
• TABLE 262 PATHAI, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 263 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 264 PATHAI, INC.: DEALS, JANUARY 2021-APRIL 2025
• TABLE 265 TEMPUS LABS, INC.: COMPANY OVERVIEW
• TABLE 266 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 267 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
• TABLE 268 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
• TABLE 269 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
• TABLE 270 QRITIVE: COMPANY OVERVIEW
• TABLE 271 DEEPPATH: COMPANY OVERVIEW
• TABLE 272 4D PATH INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 RESEARCH DESIGN
• FIGURE 2 KEY PRIMARY SOURCES
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 4 MARKET SIZE ESTIMATION PROCESS
• FIGURE 5 KEY INSIGHTS FROM INDUSTRY EXPERTS
• FIGURE 6 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY
• FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025-2030)
• FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 9 TOP-DOWN APPROACH
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
• FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
• FIGURE 16 DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET
• FIGURE 17 NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD
• FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024
• FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
• FIGURE 22 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• FIGURE 23 ECOSYSTEM ANALYSIS
• FIGURE 24 VALUE CHAIN ANALYSIS
• FIGURE 25 EUROPE: IVDR TIMELINE
• FIGURE 26 PORTER'S FIVE FORCES
• FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2017-APRIL 2025
• FIGURE 28 NUMBER OF PATENT DOCUMENTS, BY JURISDICTION
• FIGURE 29 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2017-APRIL 2025
• FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
• FIGURE 31 KEY BUYING CRITERIA, BY END USER
• FIGURE 32 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
• FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
• FIGURE 34 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD)
• FIGURE 35 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD THOUSAND)
• FIGURE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
• FIGURE 37 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
• FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2024 (USD MILLION)
• FIGURE 39 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024)
• FIGURE 40 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 41 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
• FIGURE 42 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 43 EV/EBITDA OF KEY VENDORS
• FIGURE 44 YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN PATHOLOGY VENDORS
• FIGURE 45 BRAND/PRODUCT COMPARISON
• FIGURE 46 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)
• FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 49 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 50 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
• FIGURE 51 TEMPUS: COMPANY SNAPSHOT (2024)